Grants and Contracts Details
Description
There is accumulating evidence from many directions indicating that gender plays a critical role in drug abuse.
Biological factors, including gonadal sex hormones, contribute in a significant although incompletely
understood manner, to gender differences in drug abuse. Female sex hormones have been shown to affect
central nervous system function and modulate the effects of drugs of abuse. For example, GABAA receptor
function is positively modulated by both progesterone and many sedative drugs, including the
benzodiazepines. There is evidence from preclinical in vitro and in vivo studies as well as some clinical
research suggesting that progesterone and its metabolites may enhance the behavioral effects of
benzodiazepines. The first proposed study will utilize a within-subject design to examine the separate and
combined effects of a range of doses of micronized sublingual progesterone (0, 50, 150 and 250) and oral
triazolam (0.00, 0.12 and 0.25 mg/70 kg) on the subjective, psychomotor and physiological effects of healthy
premenopausal women under conditions of low circulating sex hormones. The second study, also a withinsubject
design, will examine the effect of progesterone pretreatment on the discriminative stimulus effects of
triazolam (0.00,0.06,0.12 and 0.25 mg/70 kg) in healthy, premenopausal women, also under conditions of low
circulating sex hormones. The progesterone dose to be tested will be determined based on the results of the
initial study (i.e., the dose, inactive in isolation, that engenders the most robust potentiation of triazolam
effects). The proposed studies will help to clarify the manner in which the ovarian hormone progesterone
modulates the behavioral effects of the sedative drug triazolam. In addition, these studies will establish a
foundation for additional studies designed to further elucidate mechanisms associated with progesterone
modulation of benzodiazepine effects, thereby further informing gender differences in health and behavior. As
such, these studies will contribute towards the development of gender-specific intervention and/or prevention
strategies and health management approaches.
Status | Finished |
---|---|
Effective start/end date | 9/30/07 → 2/28/10 |
Funding
- National Institute on Drug Abuse: $106,682.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.